CONDENSED HETEROCYCLIC COMPOUND Russian patent published in 2010 - IPC C07D487/04 C07D487/16 A61K31/519 A61K31/5377 A61K31/551 A61P35/00 A61P43/00 

FIELD: chemistry.

SUBSTANCE: invention relates to new condensed compounds (versions) or their pharmaceutically acceptable salts having inhibitory effect on HER2 and/or EGFR kinase, having the following formula, for example: or , where R^1a is a hydrogen atom; R^2a is a C_1-8alkyl group, C_2-8alkenyl group or C_2-8alkynyl group, each of which is substituted with substitute(s), R^3a is a hydrogen atom or C_1-6alkyl group; or R^1a and R^2a are optionally bonded with formation or R^2a and R^3a are optionally bonded with formation of C_2-4alkylene; B^a is a benzene ring optionally substituted with 1-4 substitutes selected from halogen and optionally halogenated C_1-4alkyl; C^a is a phenyl group substituted with 1-5 substitutes selected from (i) halogen, (ii) optionally halogenated C_1-4alkyl, (iii) hydroxy- C_1-4alkyl, (iv) a 5-8-member heterocycle- C_1-4alkyl, where the said 5-8-member heterocycle contains 1-3 heteroatoms selected from a nitrogen atom, oxygen atom and optionally oxidised sulphur atom, (v) optionally halogenated C_1-4alkyloxy, (vi) cyano and (vii) carbamoyl, optionally substituted with C_1-8alkyl, and, respectively, R^2e is a C_1-4alkyl group optionally substituted with -O-(CH₂)_n-OH, where n is an integer from 1 to 4; R^3e is a hydrogen atom; B^e is a benzene ring optionally substituted with a halogen; and C^e is a phenyl group optionally substituted with halogenated C_1-4alkyl.

EFFECT: obtained new compounds can be used for treating cancer.

22 cl, 2 tbl, 280 ex